EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, A Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention

Christof Geisen, Erika Fleck, Stephan Martin Gastón Schäfer, Carmen Walter, Susanne Braeuninger, Jens Søndergaard Jensen, Douglas Sheridan, Kiran Patki, Róisín Armstrong, Bjørn Skogen, Frank Behrens, Erhard Seifried und 3 weitere

Thrombosis and Haemostasis · 2025-04 · 125 (04) · 352-363

DOI: 10.1055/a-2398-9344 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Thrombosis and Haemostasis, online erschienen am 12.09.2024. Verfasst von Christof Geisen und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen GmbH, Frankfurt am Main,…. Hauptthemen laut MEDLINE: Thrombocytopenia, Neonatal Alloimmune, Antigens, Human Platelet, Antibodies, Monoclonal, Integrin beta3. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Rallybio IPA, LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare bleeding disorder of the fetus/newborn caused by development of maternal alloantibodies against fetal human platelet antigens (HPAs), predominantly HPA-1a. Currently there are no treatments available to prevent maternal alloimmunization to HPAs or FNAIT. This proof-of-concept study (EudraCT Number: 2021-005380-49) was designed to assess the ability of subcutaneous (SC) RLYB212, a monoclonal anti-HPA-1a antibody, to eliminate HPA-1a-positive platelets in an antigen challenge model of a 30 mL fetal–maternal hemorrhage. Subjects were randomized to receive a single SC dose of RLYB212 or placebo on day 1 in a single-blinded manner, followed by transfusion of 10 × 109 HPA-1a-positive platelets on day 8. Four subjects received 0.09 mg SC RLYB212, five received 0.29 mg SC RLYB212, and two received placebo. RLYB212 achieved rapid elimination of HPA-1a-positive platelets in a concentration-dependent manner, with concentrations as low as 3.57 ng/mL meeting the prespecified proof-of-concept criterion of ≥90% reduction in platelet elimination half-life versus placebo. Following HPA-1a-positive platelet transfusion, a rapid decline was observed in the concentration of RLYB212 over a period of 2 to 24 hours, corresponding to the time needed for RLYB212 to bind to ∼10% of HPA-1a on cell surfaces. RLYB212 was well tolerated with no reports of drug-related adverse events. The data from this study are consistent with preclinical efficacy data and support the potential use of RLYB212 as a prophylactic treatment for FNAIT that prevents maternal HPA-1a alloimmunization during at-risk pregnancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thrombocytopenia, Neonatal AlloimmuneAntigens, Human PlateletAntibodies, MonoclonalIntegrin beta3HumansFemaleAdultPregnancyMaleBlood PlateletsSingle-Blind MethodPlatelet TransfusionIsoantibodiesYoung AdultProof of Concept StudyInfant, Newborn

Substanzen

Antigens, Human PlateletAntibodies, MonoclonalITGB3 protein, humanIsoantibodiesIntegrin beta3

Autor:innen und Institutionen

  • Institute of Transfusion Medicine and Immunohaematology, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen GmbH, Frankfurt am Main, Germany.
  • Division Clinical Research, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany.
  • Aixial Danmark A/S, Herlev, Denmark.
  • Rallybio, New Haven, Connecticut, United States.
  • Department of Laboratory Medicine, University Hospital of North Norway, Tromsø, Norway.
  • Division of Rheumatology, University Hospital Goethe-University Frankfurt am Main, Germany.

ORCID-Profile: Jens Kjeldsen-Kragh

Förderung

  • Rallybio IPA, LLC

Zitieren

APA

Geisen, C., Fleck, E., Schäfer, S. M. G., Walter, C., Braeuninger, S., Jensen, J. S., Sheridan, D., Patki, K., Armstrong, R., Skogen, B., Behrens, F., Seifried, E., Kjeldsen-Kragh, J., Kjær, M., & Köhm, M. (2025). A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, A Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention. Thrombosis and Haemostasis, 125(04), 352-363. https://doi.org/10.1055/a-2398-9344

Vancouver

Geisen C, Fleck E, Schäfer SMG, Walter C, Braeuninger S, Jensen JS, et al. A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, A Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention. Thrombosis and Haemostasis. 2025;125(04):352-363. doi:10.1055/a-2398-9344

BibTeX
@article{Geisen2025,
  author = {Geisen, Christof and Fleck, Erika and Schäfer, Stephan Martin Gastón and Walter, Carmen and Braeuninger, Susanne and Jensen, Jens Søndergaard and Sheridan, Douglas and Patki, Kiran and Armstrong, Róisín and Skogen, Bjørn and Behrens, Frank and Seifried, Erhard and Kjeldsen-Kragh, Jens and Kjær, Mette and Köhm, Michaela},
  title = {A Phase 1b PK/PD Study to Demonstrate Antigen Elimination with RLYB212, A Monoclonal Anti-HPA-1a Antibody for FNAIT Prevention},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {04},
  pages = {352--363},
  doi = {10.1055/a-2398-9344}
}
Kostenlos starten →